Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).

被引：0
|
作者：
Barthelemy, Philippe
Loriot, Yohann
Voog, Eric
Eymard, Jean Christophe
Ravaud, Alain
Flechon, Aude
Jaillon, Christine Abraham
Chasseray, Matthieu
Lorgis, Veronique
Hilgers, Werner
Gobert, AurElien
Le Moulec, Sylvestre
Simon, Camille
Nicolas, Emanuel
Escande, Anne
Pouessel, Damien
Josse, Constant
Solbes, Marie-Noelle
Lambert, Prisca
Thibault, Constance
机构：
[1] Inst Cancerol Strasbourg Europe, Strasbourg, France
[2] Gustave Roussy, Villejuif, France
[3] Clin Victor Hugo Ctr Jean Bernard, Le Mans, France
[4] Inst Cancerol Jean Godinot, Reims, France
[5] Bordeaux Univ, Bordeaux Univ Hosp, Bordeaux, France
[6] Ctr Leon Berard, Lyon, France
[7] Foch Hosp, Suresnes, France
[8] Ctr Finisterien Radiotherapie & Oncol Clin Pasteu, Brest, France
[9] Inst Cancerol Bourgogne, Dijon, France
[10] Avignon Provence Canc Inst, Avignon, France
[11] St Gregoire Hosp, St Gregoire, France
[12] Clin Marzet, Pau, France
[13] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France
[14] Univ Hosp Nimes, Nimes, France
[15] Clin Ste Anne, Strasbourg, France
[16] Inst Claudius Regaud IUCT Oncopole, Toulouse, France
[17] eXYSTAT, Malakoff, France
[18] Merck Sante SAS, Lyon, France
[19] Pfizer Oncol, Paris, France
[20] Univ Paris Cite, Hop Europeen Georges Pompidou, AP HP Ctr, Inst Canc Paris CARPEM, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
471
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Longterm outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.
    Perez-Valderrama, Begona
    Powles, Thomas
    Sridhar, Srikala S.
    Caserta, Claudia
    Loriot, Yohann
    Gupta, Shilpa
    Bellmunt, Joaquim
    Sternberg, Cora N.
    Wang, Jing
    Costa, Nuno
    Laliberte, Robert J.
    Di Pietro, Alessandra
    Park, Se Hoon
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [12] SPADE: Design of a real-world observational study of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (UC) in the Asia-Pacific (APAC) region.
    Su, Po-Jung
    Park, Se Hoon
    Tsai, Yu Chieh
    Kim, Miso
    Wu, Wen-Jeng
    Gao, Seasea
    Shin, Sang Joon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [13] Subgroup analyses of patients (pts) with advanced urothelial carcinoma (aUC) who had long-term progression-free survival (PFS) or overall survival (OS) with avelumab first-line maintenance (1LM) in the AVENANCE real-world study
    Barthelemy, P.
    Eymard, J-C.
    Flechon, A.
    Goupil, M. Gross
    Voog, E.
    Loriot, Y.
    Jaillon, C. Abraham
    Gobert, A.
    Chasseray, M.
    Kazan, E.
    Josse, C.
    Lambert, P.
    Paret, L.
    Thibault, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S1151 - S1152
  • [14] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100
    Aragon-Ching, J. B.
    Grivas, P.
    Loriot, Y.
    Bellmunt, J.
    Wang, J.
    Michelon, E.
    di Pietro, A.
    Powles, T. B.
    Sridhar, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1343 - S1343
  • [15] Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.
    Bellmunt, Joaquim
    Aragon-Ching, Jeanny B.
    Climent, Miguel Angel
    Sridhar, Srikala S.
    Powles, Thomas
    Cislo, Paul
    Michelon, Elisabete
    Di Pietro, Alessandra
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [16] Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100
    Grivas, P.
    Park, S. H.
    Voog, E.
    Su, W-P.
    Demey, W.
    Fong, P. C.
    Garcia, J. A.
    Jacob, N.
    Gerhold-Ay, A.
    Tyroller, K.
    Hoffman, J.
    Bellmunt, J.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1144 - S1144
  • [17] Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program
    Park, Se Hoon
    Shin, Sang Joon
    Rha, Sun Young
    Beom, Seung-Hoon
    Seo, Ho Kyung
    Keam, Bhumsuk
    Kim, Miso
    Hong, Yoon-Hee
    Yoon, Shinkyo
    Lee, Jae-Lyun
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [18] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI)
    Aragon-Ching, Jeanny B.
    Petrylak, Daniel P.
    Sridhar, Srikala S.
    Gupta, Shilpa
    Grivas, Petros
    Powles, Thomas
    Gurney, Howard
    Jacob, Natalia
    Tyroller, Karin
    Guenther, Silke
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 600 - 600
  • [19] ONCOLOGISTS' PREFERENCES FOR FIRST-LINE (1L) TREATMENT OF LOCALLY ADVANCED/ UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA (AUC)
    Grivas, P.
    Phani, V
    Chiu, K.
    Pawar, V
    Chang, J.
    Bharmal, M.
    VALUE IN HEALTH, 2022, 25 (01) : S162 - S162
  • [20] Avenue: A prospective observational study of real-world treatment patterns and treatment outcomes in patients with advanced or metastatic urothelial carcinoma treated with avelumab first-line maintenance therapy
    Gschwend, J.
    Belz, H.
    Boegemann, M.
    Niegisch, G.
    Janssen, J.
    Henrici, M.
    Schostak, M.
    Gruenwald, V
    Wille, K.
    Wunderlich, H.
    Schlack, K.
    Stark, L.
    Mundel, T.
    Grimm, M. O.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 266 - 266
12345